 |
|
 |
|
|
Online Resources for CML
| | | Contents | |
| | | General Information about CML |
|
- The NCI PDQ
patient statement on chronic myelogenous leukemia .
- The NCI PDQ
physician statement on chronic myelogenous leukemia .
-
BMTs for Chronic Myelogeneous Leukemia from
BMT Newsletter
, March 1995, Issue #28.
- The
CML Frequently Asked Questions list (FAQ) from
the MPD-NET page .
-
Chronic Myelogenous Leukemia (CML) a booklet
from the Leukemia and
Lymphoma Society of America which aims to provide
information about CML to patients and their families. In
Spanish:
Leucemia Mieloide Crónica .
- Understanding
Chronic Myeloid Leukaemia (CML) a basic introduction to CML
from CancerBACUP
an organization in England that aims to help people live with
cancer by providing information, emotional support and
counselling.
- The University of Newcastle CML
site, by Stephen G. O'Brien. This site has a lot of
information on the drug STI571, the Royal Victoria Infirmary in
Newcastle was the first UK center to this drug.
- Chronic Myelogenous
Leukemia by Emmanuel C Besa, MD and Ulrich Woermann, MD, from
the eMedicine World
Medicine Library . This is a very technical review of the
symptoms, causes, diagnosis and treatment of CML.
-
Chronic Myeloid Leukemia from CancerConsultants.com is
an overview of the treatment of CML for patients.
 | | | Journal Articles about CML |
|
-
Frequency of Major Molecular Responses to Imatinib or
Interferon Alfa plus Cytarabine in Newly Diagnosed
Chronic Myeloid Leukemia by Hughes, T.P.,
et. al., New England
Journal of Medicine , Vol. 349, No. 15: October 9,
2003, pages 1423-1432. 1106 patients with CML in
chronic phase were randomized to Imatinib (Gleevec) or
Interferon Alfa plus cytarabine as initial
therapy. After 12 months 68 percent of the Imatinib had
a complete cytogenetic response (no evidence of
chromosomal abnormalities) versus 7 percent in the
Interferon group. 39 percent of the Imatinib group
versus 2 percent of the Interferon group had a reduction
of BCR-ABL transcript levels of more then 1000
times. For those patients, 100 percent were still in
remission after 24 months.
-
Chronic Myelogenous Leukemia , Brian J. Druker,
Charles L. Sawyers, Renaud Capdeville, John M. Ford,
Michele Baccarani and John M. Goldman Hematology ,
American Society of Hematology Education Program Book
, 2001. The treatment of CML is evolving rapidly
since the introduction of STI-571 (Gleevec, imatinib
mesylate), and the use of non-myeloablative stem cell
transplants ("mini-PBSCT"). This articles provides an
overview of the resutls using STI-571 as well as an
overview on administering it, including management of
common side effects and interactions with other
drugs. In addition, recent results using Interferon and
stem cell transplants are presented.
- Hematologic
and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous
Leukemia by Kantarjian, H., et. al., New England Journal of Medicine ,
Vol. 346, No. 9: February 28, 2002, pages 645-652. (The full article
is available for free 6 months after publication, the article
abstract is available now.) 532 patients with late-chronic-phase
CML who had failed interferon alfa treated were treated with oral
Imatinib Mesylate (STI-571, Gleevec). Imatinib induced major
cytogenetic responses in 60 percent of patients and complete
hematologic responses in 95 percent. After a median follow-up of 18
months, CML had not progressed in an estimated 89 percent of patients,
and 95 percent of the patients were alive.
-
Major-Histocompatibility-Complex Class I Alleles and Antigens in
Hematopoietic-Cell Transplantation by Petersdorf, E.W.,
et. al., New England Journal of
Medicine , Vol. 345, No. 4, July 26, 2001, pages 241-247. (The
full article is available for free 6 months after publication, the article
abstract is available now.) This article reports on a study of a
large number of MUD transplants for CML done at the Fred Hutchinson Cancer Research Center
. It looked at whether HLA mismatches that are detectable only at
the DNA level are associated with a lower risk of graft failure then
mismatches that are detectable by serology. The risk of graft failure
in patients with a donor with an HLA mismatch that is detectable only
at the DNA level is not increased compared with patients with a donor
with no mismatches.
- Efficacy
and Safety of a Specific Inhibitor of the BCR-aBL Tyrosine Kinase in
Chronic Myeloid Leukemia , from the New England Journal of Medicine april
5, 2001, Vol. 344, No. 14, pages 1031-1037, by Brian J. Druker,
et. al. (registration, which is free is required). Reports on the a
Phase I trial of STI-571 (Gleevec) in the treatment of 83 patients
with CML in the chronic phase. Most patients responded to STI-571
including some who experienced a completer remission. another article
in the same edition, page 1038-1042 is activity
of a Specific Inhibitor of the BCR-aBL Tyrosine Kinase in the Blast
Crisis of Chronic Myeloid Leukemia and acute Lymphoblastic Leukemia
with the Philadelphia Chromosome by Brian J. Druker, et. al,
reports on STI-571 in patients in Blast Crisis (and also some patients
with ALL who have the Philadelphia chromosome). also an accompanying
editorial Targeting
the BCR-aBL Tyrosine Kinase in Chronic Myeloid Leukemia by
John M. Goldman, and Junia V. Melo.
- Anagrelide for
Treatment of Patients with Chronic Myelogenous Leukemia and a High
Platelet Count , Trapp, O.M.,beykirch, M.K., Petrides, P.E.,
from blood Cells, Molecules, & Diseases, Issue 2, Vol. 24: January 31,
1998. The article abstract as well as the entire article in PDF format
are available.
- Recent Experience
with bone marrow transplants in Adults recieving HLA-Identical Related
Transplants for CML , from the Fred Hutchinson Cancer Research Center
. <
- Bone
Marrow Transplants from Unrelated Donors for Patients with Chronic
Myeloid Leukemia , from the New
England Journal of Medicine april 2, 1998, Vol. 338, No. 14,
pages 962-968, by John a. Hansen,, et. al. (registration, which is
free is required). , reports on the experience at the Fred Hutchison Cancer Center with
matched unrelated donor (MUD) BMTs for CML. also an accompanying
editorial a Chance
of Cure for Every Patient with Chronic Myeloid Leukemia? by
Rudiger Hehlman in the same edition.
- Interferon
alfa-2b Combined with Cytarabine versus Interferon alone in Chronic
Myelogenous Leukemia , from the New England Journal of Medicine July
24, 1997, Vol. 337, No. 4, pages 223-229, by Francois Guilhot,
et. al. (registration, which is free is required). Reports on the
experience from the French Chronic Myeloid Leukemia Study Group with
Interferon alone and Interferon combine with low dose monthly courses
of Cytarabine (ara-C). also an accompanying editorial Optimizing
Treatment for Chronic Myeloid Leukemia by John M. Goldman in
the same edition and followup
correspondence from the November 27, 1997, Vol 337, No 22
issue.
- ABC of
clinical haematology: Chronic myeloid leukaemia , a review
article by John Goldman, from the British
Medical Journal , Vol 314, page 657, 1 March 1997.
-
Survival with Bone Marrow Transplantation Versus Hydroxyurea or
Interferon for Chronic Myelogenous Leukemia: The German CML Study
Group , article abstract from Blood Volume 91, No. 5, pages
1810-1819, 1998 along with an Editorial Commment by Hussain I. Saba,
MD, PhD from Medscape
.
-
Chronic Myelogenous Leukemia: Biology and Therapy Faderl, S,
et. al., Annals of Internal Medicine, 3 August 1999. 131:207-219. This
article provides an overview of the diagnosis, current and future
treatment options and prognosis for CML.
-
Current Status of Treatment for Chronic Myelogenous Leukemia ,
by Kolibaba, K. and Druker, B., from
Medscape Oncology . Discusses the diagnosis of CML and the
current treatment options, including Interferon Alpha, bone marrow
transplants, Hydroxyurea, Busulfan, Cytarabine and experimental agents
Homoharringtonine (HHT) and STI 571.
| | | Other Articles | |
-
Oregon Cancer Center - Leukemia Program , part
of the The Oregon
Cancer Center , Portland, Oregon. Brian Druker is
the program leader of the Hematologic Malignancies
Program and this site contains information about STI-571
(Gleevec).
-
Gleevec information from Novartis,
the manufactor of Gleevec® (imatinib mesylate),
includes a information on CML, a Frequently Asked
Question (FAQ) section and a glossary.
Glivec
information is another site by Novartis for
Healthcare Professionals outside the U.S. It seems to
contain more scientific information on Gleevec and Información
sobre Glivec.
- Alpha
Interferon in the Treatment of Chronic Myeloid Leukaemia
. Report No. 52, March, 1996 from the Development and
Evaluation Committee of the National Health Service
South & West Research & Development Directorate,
UK. .
- A warning about interferon , an article the Fred Hutchinson Cancer Research Center, Center News , about research reported at American Society of Hematology annual meeting, in December, 1997. This study lead by Dr. Claudio Anasetti, looked at survival rates of patients with CML had undergone treatment with interferon alpha prior to having a unrelated marrow transplant. The original article is: impact of pre-transplant interferon-α on outcome of unrelated donor marrow transplants for chronic myeloid leukemia in first chronic phase (article abstract only).
- Polyethylene Glycol (PEG) Intron from Leukemia Insights , a quarterly newsletter written primarily for physician, published by M D anderson Cancer Center , University of Texas Medical Center, Houston, TX.
- Guidelines for the Management of CML with Interferon alpha from Leukemia Insights Newsletter , a quarterly newsletter written primarily for physician, published by M D anderson Cancer Center , University of Texas Medical Center, Houston, TX.
- New Therapy Discovered For One Of Most Common Leukemias , a press release on the results of the Phase I clinical trial of STI 571 for CML patients in chronic phase. This is discusses the articles by Druker, et. al. from the American Society of Hematology (ASH) 1999 annual meeting. The abstracts from the ASH conference are available here . More information on STI 571 is available from the unofficial STI 571 site (which is not associated with Novartis the makers of STI 571). Information on the enrolling in clinical trials of STI 571 is available from Novartis .
|
 |
|
HOME
::
ABOUT THIS SITE
::
CONTACT
|
|
